We now demonstrate that NMT2 loss is linked to poorer prognosis in DLBCL and that NMT2 suppression occurs via hypermethylation of a CpG island found at the 5’ end of the NMT2 gene in hematologic and solid cancer tumors. This evidence concerns the gene NMT2 and diffuse large B-cell lymphoma.